Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Adial pharmaceuticals, inc save search
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
Published: 2023-10-31 (Crawled : 13:00) - adialpharma.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 2.56%
H: 4.25%
C: -3.5%
conference international pharmaceuticals medical
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism
Published: 2023-08-28 (Crawled : 12:30) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: -2.91%
alcohol pharmaceuticals research medical
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
Published: 2023-03-06 (Crawled : 21:00) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 40.95%
H: 1.35%
C: -25.19%
ad04 treatment alcohol pharmaceuticals update
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic PainPNV-5030 significantly reduced pain compared to both placebo and acetaminophen
Published: 2022-09-26 (Crawled : 14:00) - biospace.com/
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: -0.35%
H: 6.28%
C: 3.18%
pnv-5030 treatment pharmaceuticals potential positive
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis
Published: 2022-09-06 (Crawled : 13:00) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 8.33%
H: 7.23%
C: -7.12%
pnv-6005 treatment potential positive ulcerative colitis
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH
Published: 2022-05-19 (Crawled : 14:00) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 0.74%
H: 3.28%
C: 0.0%
research collaboration diabetes potential nash
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
Published: 2022-05-04 (Crawled : 13:20) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -4.79%
research collaboration potential
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
Published: 2022-02-24 (Crawled : 14:30) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 0.0%
H: 9.0%
C: 9.0%
ad04 alcohol use disorder treatment als order trial phase 3
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma
Published: 2022-02-09 (Crawled : 14:30) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 7.92%
H: 1.16%
C: -5.79%
pnv-5032 treatment als potential positive
Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04Patent covers patients with a specific genetic biomarker for the serotonin-3 receptor
Published: 2022-01-24 (Crawled : 15:00) - biospace.com/
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: -3.42%
H: 4.87%
C: 3.98%
ad04 treatment genetic als serotonin-3 order patent opioid biomarkers
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as a Drug Candidate for the Treatment of Pain
Published: 2021-10-21 (Crawled : 15:15) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: -0.24%
H: 11.51%
C: -7.67%
treatment pre-clinical positive drug preclinical
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as Drug Candidate for the Treatment of Pain
Published: 2021-10-21 (Crawled : 14:15) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: -0.24%
H: 11.51%
C: -7.67%
treatment pre-clinical positive drug preclinical
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
Published: 2021-09-30 (Crawled : 14:00) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 0.48%
H: 3.57%
C: 2.14%
alcohol use disorder treatment phase 3 trial
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderONWARD trial enrollment closed; trial completion expected in Q1 2022
Published: 2021-08-31 (Crawled : 17:00) - biospace.com/
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 2.54%
H: 3.19%
C: -3.19%
alcohol use disorder treatment phase 3 trial enroll
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
Published: 2021-08-31 (Crawled : 14:00) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 2.54%
H: 3.19%
C: -3.19%
alcohol use disorder treatment phase 3 trial enroll
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
Published: 2021-08-20 (Crawled : 15:00) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 0.32%
H: 11.82%
C: 6.71%
alcohol use disorder treatment phase 3 trial enroll
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
Published: 2021-08-10 (Crawled : 14:00) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 0.36%
H: 6.18%
C: -0.73%
treatment opioid patent
Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder
Published: 2021-01-11 (Crawled : 16:00) - biospace.com/
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 0.0%
H: 10.36%
C: 7.25%
patent opioid treatment
Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder
Published: 2020-12-17 (Crawled : 17:00) - biospace.com/
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 0.52%
H: 3.11%
C: -2.59%
phase 3 trial treatment enroll
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.